Back to catalogue
ANCR
Animalcare Group PLC
490/1000 Overall fit
AI beneficiary 35% 20
Operating leverage 25% 70
Valuation 25% 60
Downside protection 15% 65
First-pass take
Strong operational execution (52.6% EBITDA growth, 500bp margin expansion) and fortress balance sheet (0.7x leverage). However, zero AI exposure—traditional veterinary pharma with biologics pipeline. Pending Charterhouse acquisition introduces material uncertainty. Fair valuation at 13x EBITDA/21x earnings insufficient to justify deep-dive.
Flags
no-ai-exposuregoing-concern-uncertaintyacquisition-pendingm-and-a-activecyclical-equine